Transchem Limited. Intrinsic Value
Valuation
Blended fair value using DCF and peer comparison methods.
Transchem Limited. Intrinsic Value Analysis
A current price is not available for Transchem Limited. (TRANSCHEM), so a price-to-value comparison cannot be shown. Understock's estimated intrinsic value is ₹244 per share.
The displayed estimate uses the available peer-based value of ₹244; a DCF estimate is not currently available. Peer comparison uses 8 matched industry companies and contributing P/E, P/B multiples.
For context, available company data reports P/E of 58.1×. These metrics describe the business and are not separate intrinsic-value estimates.
How Understock Calculates Intrinsic Value
Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. For this page, the available displayed estimate comes from peer valuation. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.
Review this company's DCF valuation · Learn how DCF works · Use the DCF calculator · See Transchem Limited. peer valuation · What intrinsic value means
The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.
Transchem Limited. Peer Comparison
How this company stacks up against sector peers on valuation and quality metrics.
Healthcare · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Transchem Limited. TRANSCHEM · you | ₹390 Cr | 58.1× | 5.0× | — | 8.7% | — | — |
| Sector median | — | 33.2× | 5.2× | 13.4× | 13.9% | 0.2% | -1.9% |
| Aarti Drugs Limited AARTIDRUGS | ₹3,901 Cr | 20.0× | 2.5× | 13.4× | 12.6% | 7.6% | -1.9% |
| Unichem Laboratories Limited UNICHEMLAB | ₹3,793 Cr | 22.8× | 1.6× | — | 7.0% | 0.0% | — |
| Novartis India Limited NOVARTIND | ₹3,671 Cr | 41.0× | 4.7× | 31.9× | 11.4% | 26.3% | -2.2% |
| Kwality Pharmaceuticals Limited KPL | ₹3,574 Cr | 44.1× | 14.7× | — | 33.4% | 0.2% | — |
| SMS Pharmaceuticals Limited SMSPHARMA | ₹3,377 Cr | 37.3× | 5.7× | — | 15.2% | 0.1% | — |
| Dishman Carbogen Amcis Limited DCAL | ₹2,821 Cr | 31.9× | 0.5× | 5.9× | 1.5% | 3.3% | 6.7% |
| Vimta Labs Limited VIMTALABS | ₹2,754 Cr | 34.6× | 8.1× | — | 23.6% | 0.2% | — |
| Fredun Pharmaceuticals Limited FREDUN | ₹2,560 Cr | 19.2× | 19.6× | — | 34.0% | 0.1% | — |
Transchem trades at a premium to sector peers on P/E (58.1× vs median 33.2×). The market is pricing in higher growth — worth verifying whether recent revenue trends support that expectation.
Business quality
Valuation
Returns
Growth
Efficiency
Liquidity & Solvency
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.